78 completed, 9 terminated, 4 withdrawn, 3 unknown. 96 Phase 3, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 96 | Completed 78, Terminated 9, Withdrawn 4, Unknown 3, Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 7 | Completed 6, Not yet recruiting 1 |
Follow Sitagliptin: new trials by email Literature Review of Sitagliptin trials Research Report on Sitagliptin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes Tirzepatide, Pioglitazone, Sitagliptin - Type 2 Diabetes (Adult Onset) | Phase 3 | Recruiting | The University of Texas Health Science Center at San Antonio | 256 | 2024-11-07 | 2026-03-10 |
| Effects of Sitagliptin in Relatives of T1D Patients Sitagliptin, Professional CGM - Type 1 Diabetes | Phase 2 / Phase 3 | Not yet recruiting | University of Milan | 70 | 2023-07-01 | 2023-05-10 |
| The Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic Patients Sitagliptin - Covid19, Diabetes Mellitus, Type 2 | Phase 3 | Unknown | University of Milan | 170 | 2021-12-29 | 2021-09-28 |
| Oral Hypoglycemic Therapy for Monogenic Variant Carriers of the Joslin Medalist Study Metformin Extended Release Oral Tablet, Sitagliptin - Type 1 Diabetes, Monogenic Diabetes | Phase 2 / Phase 3 | Completed | Joslin Diabetes Center | 3 | 2021-08-26 | 2025-02-24 |
| Effects of SGLT2i on the Cognitive Function in T2DM Patient (ESCDP) Canagliflozin, Sitagliptin - Diabetes Mellitus, Type 2, Cognitive Functions Confusion | Phase 3 | Completed | Third Military Medical University | 100 | 2021-07-01 | 2024-05-30 |
| A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes Oral semaglutide, Sitagliptin, Placebo (oral semaglutide) - Diabetes Mellitus, Type 2 | Phase 3 | Completed | Novo Nordisk A/S | 1441 | 2019-07-29 | 2024-10-01 |
| Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects Bexagliflozin, Sitagliptin, Placebo for sitagliptin - Type 2 Diabetes Mellitus | Phase 3 | Completed | Theracos | 386 | 2017-10-12 | 2021-06-22 |
| Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT) Semaglutide 0.5 mg, Semaglutide 1.0 mg, Sitagliptin placebo - Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | Completed | Novo Nordisk A/S | 868 | 2017-08-28 | 2021-03-02 |
| Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and Metformin Ipragliflozin, Sitagliptin - Type 2 Diabetes Mellitus | Phase 3 | Completed | Seoul National University Bundang Hospital | 170 | 2017-04-25 | 2022-10-04 |
| Effectiveness & Tolerability of Novel, Initial Triple Combination Therapy vs Conventional Therapy in Type 2 Diabetes triple combination therapy, Stepwise add-on therapy - Diabetes Mellitus, Type II | Phase 3 | Unknown | Korea University Anam Hospital | 104 | 2016-12-01 | 2016-10-27 |
| Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus. semaglutide, sitagliptin - Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | Completed | Novo Nordisk A/S | 504 | 2016-09-20 | 2022-07-20 |
| A Study of the Safety and Efficacy of Sitagliptin Addition During Metformin Up-titration (MK-0431-848) Sitagliptin, Placebo, Metformin IR - Type 2 Diabetes Mellitus | Phase 3 | Completed | Merck Sharp & Dohme LLC | 458 | 2016-06-16 | 2019-02-28 |
| Randomized Sitagliptin Withdrawal Study (MK-0431-845) Sitagliptin, Placebo to sitagliptin, Metformin - Type 2 Diabetes Mellitus | Phase 3 | Completed | Merck Sharp & Dohme LLC | 746 | 2016-05-09 | 2019-02-25 |
| Accelerated Wound Healing in Diabetic Ulcers by Sitagliptin Sitagliptin, Placebo - Diabetic Foot | Phase 3 | Withdrawn | Wolfgang-Michael Franz | 2016-03-01 | 2016-09-15 | |
| Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes semaglutide, sitagliptin, placebo - Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | Completed | Novo Nordisk A/S | 1864 | 2016-02-15 | 2022-07-20 |
| Double-blind Ipragliflozin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin (MK-0431J-843) Ipragliflozin, Placebo, Sitagliptin - Type 2 Diabetes Mellitus | Phase 3 | Completed | Merck Sharp & Dohme LLC | 143 | 2015-11-09 | 2018-09-04 |
| Double-blind Sitagliptin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Ipragliflozin (MK-0431J-842) Sitagliptin, Placebo, Ipragliflozin - Type 2 Diabetes Mellitus | Phase 3 | Completed | Merck Sharp & Dohme LLC | 141 | 2015-11-05 | 2018-08-31 |
| Ipragliflozin Add-on Long-term Study in Japanese Participants With Type 2 Diabetes Mellitus on Sitagliptin (MK-0431J-849) Ipragliflozin, Sitagliptin - Type 2 Diabetes Mellitus | Phase 3 | Completed | Merck Sharp & Dohme LLC | 77 | 2015-10-26 | 2018-09-04 |
| A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838) Sitagliptin, Dapagliflozin, Metformin - Type 2 Diabetes Mellitus | Phase 3 | Completed | Merck Sharp & Dohme LLC | 614 | 2015-10-20 | 2018-11-20 |
| Sitagliptin Therapy and Kinetics of Inflammatory Markers Sitagliptin, Placebo - Type 2 Diabetes Mellitus | Phase 3 | Completed | Laval University | 20 | 2015-08-01 | 2020-05-13 |
Showing 20 of 96. Sign in to see all of them.
Diabetes Mellitus, Type 2 (84) · Diabetes Mellitus (24) · Diabetes Mellitus, Type 1 (3) · Inflammation (3) · Renal Insufficiency (3) · Cardiovascular Diseases (2) · Hyperlipidemias (2) · Renal Insufficiency, Chronic (2) · Atherosclerosis (1) · Body Weight (1) · COVID-19 (1) · Confusion (1) · Cystic Fibrosis (1) · Diabetic Foot (1) · Endocrine System Diseases (1)
Merck Sharp & Dohme LLC (31) · Novo Nordisk A/S (9) · AstraZeneca (6) · Janssen Research & Development, LLC (3) · Laval University (3) · Boehringer Ingelheim (2) · GlaxoSmithKline (2) · Intarcia Therapeutics (2) · Michael A. Nauck (2) · Novartis (2) · Phenomix (2) · Sanofi (2) · Takeda (2) · University of Milan (2) · Washington University School of Medicine (2)
United States (35) · Mexico (16) · South Korea (16) · Canada (15) · India (15) · Germany (14) · South Africa (13) · Poland (12) · Argentina (11) · Romania (11) · Spain (11) · Russia (10) · Hungary (9) · United Kingdom (9) · Brazil (8)
Kevin E Yarasheski, PhD (2) · Michael A. Nauck, Prof. Dr. (2) · Patrick Couture, MD, PhD (2) · Arlene A Stecenko, MD (1) · Astra Zeneca (1)
PMID 32998732, PMID 24517339, PMID 24742013, PMID 24786834, PMID 24918789, PMID 25329038, PMID 25813214, PMID 26121561, PMID 26373629, PMID 26580237, PMID 27600862, PMID 27977934, PMID 28197834, PMID 28241822, PMID 28327140, PMID 31797522, PMID 31903692, PMID 32306296, PMID 32324065, PMID 32324082, PMID 32372382, PMID 32648108, PMID 38770818, PMID 23522121, PMID 23748506, PMID 23748507, PMID 26579834, PMID 30880443, PMID 32267058, PMID 32700393, PMID 33660198, PMID 34033212, PMID 35373893, PMID 37178435, PMID 39963952, PMID 10752702, PMID 16033281, PMID 18539916, PMID 18539917, PMID 18784090, PMID 19073764, PMID 19114612, PMID 19336687, PMID 19689275, PMID 20417856, PMID 20580422, PMID 21199268, PMID 21205123, PMID 21309842, PMID 21355967
2015 (5), 2008 (4), 2014 (3), 2009 (1), 2018 (1), R01DK097554 (1), U01DK098246 (1)